ImmunityBio, Inc. (IBRX)
ImmunityBio (IBRX) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
ImmunityBio (IBRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ImmunityBio Q1 Earnings Preview: I Fear A Selloff, But Am Long-Term Bullish
ImmunityBio, Inc.'s stock has significantly declined despite my previous "Buy" ratings, primarily due to a $100m fundraising and market selloff in December. Founder Dr. Patrick Soon-Shiong's vision for Anktiva as a groundbreaking cancer therapy remains strong, with promising data and potential label expansions in multiple oncology fields. Short-term concerns include high cash burn, premium pricing, and BCG shortages, which may lead to a stock selloff after Q1 earnings.
ImmunityBio: Taking Care Of Business
ImmunityBio, Inc.'s recent progress on Anktiva and rBCG, including FDA submissions and collaborations, positions the company for significant revenue growth despite current financial challenges. The severe BCG shortage impacts Anktiva's growth, but ImmunityBio's rBCG efforts could fill the supply gap and potentially redefine NMIBC treatment. Despite strong commercial momentum, ImmunityBio's financial health remains a concern, with a quarterly cash burn rate of $104.4M and a cash runway of less than four months.
ImmunityBio: BCG Shortage And Tariff Risks Could Stifle Anktiva's Commercial Momentum
ImmunityBio faces significant operational risks due to reliance on international BCG supplies and competition from Adstiladrin in NMIBC treatment. Financially, ImmunityBio struggles with high cash burn, limited cash runway, and substantial debt, despite backing from billionaire founder Dr. Patrick Soon-Shiong. Anktiva's market adoption is uncertain beyond NMIBC, with potential hurdles in expanding to other indications like NSCLC, ovarian cancer, and TNBC.
ImmunityBio (IBRX) Reports Q4 Loss, Misses Revenue Estimates
ImmunityBio (IBRX) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.26. This compares to loss of $0.19 per share a year ago.
ImmunityBio: Making Its Next Strikes After Bladder Cancer Approval
ImmunityBio, Inc.'s Anktiva, approved for bladder cancer, shows promise for expansion into other solid tumors, with key trials ongoing in lung and colorectal cancers. Financial challenges persist, but recent product sales and supportive financing extend the cash runway, providing a potential growth opportunity. Strengths include data supporting new approvals and expanding Anktiva's market, though risks involve unclear lung cancer market size and significant liabilities.
IBRX Stock Soars on Completing Filing for Cancer Therapy in EU & UK
ImmunityBio stock rises 27% on completing the regulatory filing process in the EU and the U.K. for the Anktiva/BCG combo to treat NMIBC CIS patients.
ImmunityBio Stock Trading Higher On Updates From Bladder Cancer Trials: Details
On Wednesday, ImmunityBio, Inc. IBRX released progress in its ongoing FDA discussions regarding three areas of its clinical development pipeline in non-muscle invasive bladder cancer (NMIBC) and non-small cell lung cancer (NSCLC).
ImmunityBio: Forging A New Plan After Recent $100 Million Offering
ImmunityBio's recent $100M public offering was necessary to support ANKTIVA's commercialization and pipeline programs, despite the dilution and lower offering price of $3 per share. The company's cash burn rate and financial health remain concerns, but ANKTIVA's impressive performance and future milestones could drive substantial growth and extend the cash runway. IBRX's financial risks persist, and multiple offerings may be needed before profitability, but the potential for explosive revenue growth by 2029 supports a bullish outlook.
ImmunityBio: Despite Share Price & Funding Woes, Muddy Path To Long-Term Success
ImmunityBio's Anktiva shows promise with potential peak revenues of ~$900m annually, but faces significant competition and financial challenges, including a poorly timed $100m fundraising effort. Despite recent setbacks, including a Q3 net loss of $80m and a cash position of $130m, I maintain a "Buy" rating, anticipating positive 2025 catalysts. Anktiva's efficacy in NMIBC and potential in NSCLC + other cancers are potentially compelling, but the company needs substantial funding to complete ongoing and planned clinical studies.
Wall Street Analysts Think ImmunityBio (IBRX) Could Surge 184.43%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 184.4% in ImmunityBio (IBRX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
ImmunityBio (IBRX) Reports Q3 Loss, Tops Revenue Estimates
ImmunityBio (IBRX) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to loss of $0.19 per share a year ago.
